Related Experiment Video

Updated: Nov 27, 2025

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

2.5K

Trastuzumab-Induced Thrombocytopenia Correlated by Drug-Dependent Platelet Antibodies

Kathleen Sullivan1, Lynne S Kaminer1, David L Grinblatt1

  • 1NorthShore University HealthSystem, Evanston, IL.

JCO Oncology Practice
|December 3, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

5.7K
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.0K

Related Experiment Videos

Last Updated: Nov 27, 2025

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

2.5K
High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

5.7K
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.0K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

881
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
881

Articles linked to this work by shared authors, journal, and citation graph.

RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Reframing Women's Health in Kidney Disease: Sex Differences, Gender Disparities, and Clinical Imperatives - Introduction to a Special Series.

Kidney360·2026

Cardiovascular-Kidney-Metabolic Syndrome in Women: Bridging Nephrology and the Female Cardiometabolic Disparity.

Kidney360·2026

Monovalent Anti-FcγRIIA Antibody Blocks Immune-Mediated Thrombocytopenia and Thrombosis With Minimal Adverse Side Effects in Mice.

Arteriosclerosis, thrombosis, and vascular biology·2026

Direct glycoprotein-specific platelet autoantibodies detected in a majority of patients with persistent chemotherapy-induced thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2026

Non-PF4/heparin-binding, platelet-activating antibodies in heparin-induced thrombocytopenia.

Blood·2026

Mapping the Canadian Oncology Physician Workforce: A Review of Training, Distribution, and Systemic Pressures Across Oncology-Related Physician Specialties.

JCO oncology practice·2026

Reproducibility Status of Economic Evaluations of Cancer Drugs: An Assessment of 150 Cost-Effectiveness Models.

JCO oncology practice·2026

A Decade of QOPI in Spain: From Quality Measurement to Continuous Improvement in Oncology Practice.

JCO oncology practice·2026

Promoting High-Quality, Accessible Cancer Care for People With Disabilities.

JCO oncology practice·2026

Novel Tool to Predict Primary Tumor Location in the Setting of Metastatic Cancer With Unknown Primary.

JCO oncology practice·2026

Participation of Patients With Gynecologic Cancer in Phase I Clinical Trials: Experience From Two National Cancer Institute-Designated Comprehensive Cancer Centers.

JCO oncology practice·2026

Ubiquitin signaling in tumor-associated macrophage reprogramming: mechanisms and therapeutic opportunities in cancers.

Biomarker research·2026

In primary human lymphocytes, the triazole fungicide cyproconazole impairs regulatory B cell interleukin-10 expression and induces T cell senescence.

Environmental toxicology and pharmacology·2026

Targeting MMGT1 enhances immunotherapy efficacy in triple-negative breast cancer.

Cell reports. Medicine·2026

CTLA4 rs3087243-A-linked haplotype is associated with increased CTLA-4 expression and suppressive function in human regulatory T cells.

Journal of immunology (Baltimore, Md. : 1950)·2026

pH-responsive biomimetic liposomes enhance targeted immunotherapy of bladder cancer.

Science China. Life sciences·2026

[Features of local and systemic production of major immune response cytokines in epithelial lacrimal gland tumors].

Vestnik oftalmologii·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us